Skip to Main Content

Paper Details

Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825.
Neurooncol Adv
1
2022
Myelotoxicity, Patients, anticonvulsant, glioblastoma, leukopenia, minor allele, myelotoxicity, neutropenia, patients, polymorphisms, temozolomide, thrombocytopenia
Author NameAffiliation
Michael E ScheurerBaylor College of Medicine
Erik P SulmanM D Anderson Cancer Center
Erik P SulmanLaura and Isaac Perlmutter Cancer Center at NYU Langone
Erik P SulmanM D Anderson Cancer Center
Erik P SulmanLaura and Isaac Perlmutter Cancer Center at NYU Langone
Stephanie L Pugh
  • 1 - 6

Datasets

Release 1.2